399 related articles for article (PubMed ID: 2670519)
1. Immunosuppressive drugs in inflammatory bowel disease. A review of their mechanisms of efficacy and place in therapy.
Hawthorne AB; Hawkey CJ
Drugs; 1989 Aug; 38(2):267-88. PubMed ID: 2670519
[TBL] [Abstract][Full Text] [Related]
2. Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease.
Hanauer SB; Stathopoulos G
Drug Saf; 1991; 6(3):192-219. PubMed ID: 1676590
[TBL] [Abstract][Full Text] [Related]
3. Drug therapy of inflammatory bowel disease.
Sack DM; Peppercorn MA
Pharmacotherapy; 1983; 3(3):158-76. PubMed ID: 6136027
[TBL] [Abstract][Full Text] [Related]
4. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
[TBL] [Abstract][Full Text] [Related]
5. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
6. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
Nørgård BM
Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
[TBL] [Abstract][Full Text] [Related]
7. Comparative tolerability of treatments for inflammatory bowel disease.
Stein RB; Hanauer SB
Drug Saf; 2000 Nov; 23(5):429-48. PubMed ID: 11085348
[TBL] [Abstract][Full Text] [Related]
8. Azathioprine: an update on clinical efficacy and safety in inflammatory bowel disease.
Lamers CB; Griffioen G; van Hogezand RA; Veenendaal RA
Scand J Gastroenterol Suppl; 1999; 230():111-5. PubMed ID: 10499471
[TBL] [Abstract][Full Text] [Related]
9. How important is onset of action in ulcerative colitis therapy?
Masson S; Nylander D; Mansfield JC
Drugs; 2005; 65(15):2069-83. PubMed ID: 16225364
[TBL] [Abstract][Full Text] [Related]
10. A practical guide to the management of distal ulcerative colitis.
Ardizzone S; Bianchi Porro G
Drugs; 1998 Apr; 55(4):519-42. PubMed ID: 9561342
[TBL] [Abstract][Full Text] [Related]
11. [Inflammatory bowel diseases: conservative therapy].
Bansky G
Ther Umsch; 1991 Jul; 48(7):464-70. PubMed ID: 1926006
[TBL] [Abstract][Full Text] [Related]
12. Azathioprine or 6-mercaptopurine for inflammatory bowel disease: do risks outweigh benefits?
Su CG; Stein RB; Lewis JD; Lichtenstein GR
Dig Liver Dis; 2000; 32(6):518-31. PubMed ID: 11057928
[TBL] [Abstract][Full Text] [Related]
13. Medical therapy of inflammatory bowel disease for the 21st century.
Robinson M
Eur J Surg Suppl; 1998; (582):90-8. PubMed ID: 10029372
[TBL] [Abstract][Full Text] [Related]
14. Immunosuppressive therapy in pediatric inflammatory bowel disease: results of a survey of the North American Society for Pediatric Gastroenterology and Nutrition. Subcommittee on Immunosuppressive Use of the Pediatric IBD Collaborative Research Forum.
Markowitz J; Grancher K; Mandel F; Daum F
Am J Gastroenterol; 1993 Jan; 88(1):44-8. PubMed ID: 8420272
[TBL] [Abstract][Full Text] [Related]
15. Low dose methotrexate in inflammatory bowel disease: current status and future directions.
Schröder O; Stein J
Am J Gastroenterol; 2003 Mar; 98(3):530-7. PubMed ID: 12650783
[TBL] [Abstract][Full Text] [Related]
16. [Pharmacotherapy of inflammatory bowel disease].
Jojić N
Acta Chir Iugosl; 2000; 47(1-2):51-5. PubMed ID: 10953366
[TBL] [Abstract][Full Text] [Related]
17. Mesalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in chronic inflammatory bowel disease.
Brogden RN; Sorkin EM
Drugs; 1989 Oct; 38(4):500-23. PubMed ID: 2684592
[TBL] [Abstract][Full Text] [Related]
18. Optimizing therapy for inflammatory bowel disease.
Robinson M
Am J Gastroenterol; 1997 Dec; 92(12 Suppl):12S-17S. PubMed ID: 9395347
[TBL] [Abstract][Full Text] [Related]
19. Optimizing conventional therapy for inflammatory bowel disease.
Schwartz M; Cohen R
Curr Gastroenterol Rep; 2008 Dec; 10(6):585-90. PubMed ID: 19006615
[TBL] [Abstract][Full Text] [Related]
20. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
